Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Global Sales Information
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 4
2022 Revenue in Millions : 0
Growth (%) : Acquired from Seagen
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 131
2023 Revenue in Millions : 4
Growth (%) : 3,175
ABOUT THIS PAGE